



Report of two cases
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ABSTRACT - We report on two epileptic patients who developed acute psychosis after the use of topiramate
(TPM). One patient exhibited severe psychomotor agitation, heteroaggressiveness, auditory and visual
hallucinations as well as severe paranoid and mystic delusions. The other patient had psychomotor agitation,
depersonalization, derealization, severe anxiety and deluded that he was losing his memory. Both patients
had to be taken to the casualty room. After interruption of TPM in one patient and reduction of dose in the
other, a full remission of the psychotic symptoms was obtained without the need of antipsychotic drugs.
Clinicians should be aware of the possibility of development of acute psychotic symptoms in patients undergoing
TPM treatment.
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Episódio psicótico agudo induzido por topiramato: relato de dois casos
RESUMO - Relatamos dois pacientes epilépticos que manifestaram quadro psicótico agudo induzido por
topiramato (TPM). Um paciente apresentou agitação psicomotora grave, heteroagressividade, alucinações
auditivas e visuais, e delírios de conteúdo paranóide e místico. O outro paciente apresentou agitação psico-
motora, despersonalização, desrealização, ansiedade intensa e delírio de que estava perdendo a memória. Ambos
os pacientes foram conduzidos ao serviço de emergência e, após a interrupção do TPM em um deles e redução
da droga em outro, houve remissão total dos sintomas psicóticos sem necessidade de medicação antipsicótica.
Alertamos os clínicos para o risco de surgimento de sintomas psicóticos em pacientes em uso do TPM.
PALAVRAS-CHAVE: transtornos psiquiátricos, alucinações, delírios, topiramato.
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Topiramate (TPM) is an antiepileptic drug (AED)
used as add-on therapy for generalized and partial
seizures that are resistant to other antiepileptic
drugs1- 6. It has also been proposed as a mood stabi-
lizer for patients with bipolar disorders who have
not responded to the traditional treatments7- 9. Neu-
ropsychiatric symptoms may emerge after the use
of TPM, the most common complaints are: somno-
lence, dizziness, tiredness, ataxia, headache, depres-
sion, and cognitive impairment such as mental con-
fusion, slow reasoning, speech difficulty, and distur-
bance of memory10-18. These symptoms ranged from
moderate to severe, however, they progressively
improved as treatment went on.
There are few reports in the literature regarding
the association of TPM with psychotic disorders19, 20.
The majority of the psychotic symptoms reported in
scientific meetings lack in details11, 21, 22. Patients with
history of prior psychotic or depressive symptoms
had a tendency to develop the same type of mood
disorder when put on TPM23.
The purpose of this paper is to report on two
patients with epilepsy who presented psychotic out-
bursts after the use of TPM.
CASES
Patient A - A 42-year old male, engineer, married with
two children. He had been treated for epileptic seizures
since the age of two when he had his first episode of
febrile seizures. Throughout his infancy he had several
febrile seizures and later on developed partial complex
seizures, in the absence of fever, with secondary generali-
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zation, once a week. He had no family or personal history
of psychiatric disorders. Between 1997 and 2000 he had
ten electroencephalograms performed: five showed epi-
leptiform activity in right fronto-temporal region; one sho-
wed epileptiform activity in left fronto-temporal region;
two intermittent slow waves in right temporal region; one
intermittent slow waves in left temporal region; and one
was normal. Interictal brain SPECT (1997) suggested hy-
poperfusion in the right temporal region. Magnetic reso-
nance imaging (MRI) displayed bilateral hippocampal at-
rophy with left-sided predominance and a small lesion in
the corpus callosum.
He was treated with several AEDs in monotherapy and
polytherapy, but was never seizure free. As he had been
on carbamazepine CR 1600 mg/day over a year without
much improvement, he was put on TPM 50 mg/day. This
dose was gradually increased to 300 mg daily. There were
no significant side effects but a mild difficulty in recollect-
ing recent facts. As the seizures did not improve, the TPM
dosage was increased from 300 mg to 350 mg/day. Only
one day after being on 350 mg/day, he presented a full-
blown psychotic episode: he woke up about 3 a.m. with
severe psychomotor agitation, verbal and physical hetero-
aggressiveness, disorientation in time and space as well
as regarding himself, saying that a serious bus accident
with a great number of fatal victims was bound to hap-
pen and that he had received a mission from God to save
people. He also had visual and auditory hallucinations:
vision of Our Lady telling him that his epileptic seizures
had been cured; and severe paranoid ideas of being haun-
ted by the police and other persecutory auditory halluci-
nations. He was taken to a psychiatric outpatient facility
where he became more agitated, broke objects and dam-
aged the cars parked in the vicinity. He had to be stopped
by the police and taken to a psychiatric hospital, where
he was put on diazepam. Carbamazepine was maintained
and TPM was withdrawn. He was then transferred to the
Psychiatric Unit of the General Hospital of the State Uni-
versity of Campinas, where he stayed for 11 days. Total
remission of the psychotic symptoms took place within
48 hours after TPM was completely taken off. This epi-
sode was unrelated to epileptic seizures. He was kept on
diazepam for several days because of his high anxiety and
carbamazepine CR 1600 mg/day was maintained. There
was no need for antipsychotic medication and stopping
TPM did not affect the frequency or the clinical features
of the epileptic seizures.
Patient B - A 41-year old female, divorced with two
children, who worked as a nanny. She was being treated
for temporal lobe epilepsy. She has had complex partial
seizures with secondary generalization since the age of
12. From 1997 to 2000 five electroencephalograms were
carried out: one displayed bilateral epileptiform activity in
frontal regions; two showed epileptiform activity in right
temporal region; and two were normal. The CAT scan rev-
eled mild cerebellar atrophy and MRI showed mild diffuse
cerebellar atrophy, without abnormalities in brain struc-
tures.
She underwent monotherapy as well as polytherapy
with several AEDs which failed to bring the seizures under
control. Over a period of 2 years she was treated with
valproic acid twice daily in a total of 1000 mg/day. Then
TPM 50mg/day was introduced and gradually increased
to 100 mg/day taken twice. As the seizures were not con-
trolled, the dosage of TPM was increased to 150 mg per
day and on this very same day, the patient reported a
“strong strange feeling” in relation to her environment,
depersonalization, derealization, severe anxiety, fear, rest-
lessness, and psychomotor agitation. She shouted phrases
like “I’m going mad”, “I’m losing my memory” and “no-
body believes in me“. She was taken to the casualty room
and medicated with diazepam. TPM was reduced from
150 mg to 50 mg/day which alleviate psychomotor agita-
tion and the other symptoms. There was no need for an-
tipsychotic medication. Again this psychotic episode was
unrelated to the patient’s epileptic seizures and she had
no previous history of psychiatric disorders.
DISCUSSION
Although topiramate has been reported to be
associated with various adverse effects like dizziness,
giddiness, tiredness, psychomotor slowness, diffi-
culty in attention and concentration, memory impair-
ment, loss of weight and nephrolithiasis, it is con-
sidered a safe drug with good tolerance and favor-
able pharmacokinetics24, 25. Despite the fact that its
plasmatic level is lowered by drugs that induce he-
patic metabolism4, it has relatively few adverse re-
actions and very little interaction with other medi-
cations26. When administered with carbamazepine,
a potent enzymatic Cytochrome P450 inducer27,28,
TPM undergoes 40% reduction of its plasmatic lev-
els and clearance28. On the other hand, plasma lev-
els of carbamazepine or its epoxide metabolite does
not change significantly when TPM is added29. The
simultaneous use of TPM and valproate increases the
plasma levels of the first by 15%. This has to be taken
into account if valproate is eventually withdrawn.
TPM, on the other hand, increases valproate clear-
ance, thus reducing its plasma levels29.
Although Aldenkamp et al.17 claim that the risk
of TPM impairing cognitive functions is relatively
small in comparison with valproate, they report that
patients on TPM did worse on short-term verbal me-
mory test. In the same vein, TPM was shown to im-
pair cognitive functioning, especially as regards me-
mory18. TPM may interfere with mnemonic process,
however, it is hard to judge the extent of it. Accord-
ing to ICD-10 criteria30 the two reported cases were
diagnosed as acute psychotic disorder. The clinical
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features appeared suddenly and within a few days
after increasing the TPM dosage. However, they
quickly remitted after TPM was taken off or reduced.
The frequency of psychotic episodes related to
TPM is low and the most common symptoms were
delusions, visual and auditory hallucinations. Data
on the adverse effects of TPM report only few cases
of psychotic symptoms such visual and auditory hal-
lucinations and paranoid delusions15,18, and these
patients eventually warranted hospitalization18.
The risk of psychotic symptoms due to the inter-
action of therapeutic doses of TPM and carbama-
zepine needs further investigation. However, this in-
teraction upon reducing the serum level of TPM, is
likely “to protect” the patient from the risk of TPM
intoxication provided that both drugs are in the
therapeutic range. Therefore, the concomitant use
of TPM and carbamazepine cannot be taken as re-
sponsible for the psychotic symptoms presented
by the patients. These acute psychotic episodes seem
to be have been entirely due to the use of TPM. An-
other finding that lends support to this hypothesis
is the complete remission of the psychotic symptoms
upon the withdrawal of TPM, although carbamaze-
pine was maintained. Moreover, these patients did
not need any antipsychotic medication. Only diaz-
epam was added to reduce the patients’ anxiety. .
REFERENCES
1. Brown SD, Wolf HH, Swinyard EA, Twyman RE, White HS. The novel
anticonvulsant topiramate enhances GABA-mediated chloride flux
(Abstract). Epilepsia 1993;34(Suppl 2):122.
2. Ben-Menachem E, Henriksen O, Dam M, et al. Double-blind, placebo-
controlled trial of topiramate as add-on therapy in patients with re-
fractory partial seizures. Epilepsia 1996;37:539-543.
3. Faught E, Wilder BJ, Ramsay RE, et al. The topiramate YD Study Group.
Neurology 1996;46:1684-1690.
4. Privitera MD. Topiramate: a new antiepileptic drug. Ann Pharmacother
1997;31:1164-1173.
5. Biton V. Preliminary open-label experience with topiramate in primary
generalized seizures. Epilepsia 1997;38(Suppl 1):42-44.
6. Reife RA, Pledger G, Wu SC. Topiramate as adjunctive therapy in re-
fractory partial epilepsy: pooled analysis data from five double-blind,
placebo-controlled trials. Epilepsia 1997; 38(Suppl 1):31-33.
7. Marcotte D. Use of topiramate, a new anti-epileptic , as a mood stabi-
lizer. J Affect Disord 1998;50:245-251.
8. McElroy SL, Suppes T, Keck PE, et al. Open-label adjunctive topiramate
in the treatment of bipolar disorders. Biol Psychiatry 2000;47:1025-1033.
9. Calabrese JR. Update on the use of topiramate in bipolar disorder (Ab-
stract). Am Psychiat Assoc 2000;44A:13-18.
10. Shorvon SD. Safety of topiramate: adverse events and relationships to
dosing. Epilepsia 1996; 37(Suppl 2):18-22.
11. Betts T, Smith K, Khan G. Severe psychiatric reactions to topiramate.
Epilepsia 1997;38 (Suppl 3):64.
12. Rosenfeld WE, Sachdeo RC, Faught RE, Privitera M. Long-term expe-
rience with topiramate as adjunctive therapy and as monotherapy in
patients with partial onset seizures: retrospective survey of open-label
treatment. Epilepsy 1997;38(Suppl 1):34-36.
13. Sander JWAS. Practical aspects of the use of topiramate in patients
with epilepsy. Epilepsia 1997;38(Suppl 1):56-58.
14. Matsuura M, Suzuki T, Sakai T, Kojima T. Anticonvulsivant-related
psychoses in epilepsy. Epilepsia 1998;39(Suppl 5):59-60.
15. Kellet MW, Smith DF, Stockton PA, Chadwick DW. Topiramate in clini-
cal practice: first year’s postlicensing experience in a specialist epilepsy
clinic. J Neurol Neurosurg Psychiatry 1999;66:759-763.
16. Martin R, Kuzniecky R, Ho S et al. Cognitive effects of topiramate,
gabapentin, and lamotrigine in healthy young adults. Neurology
1999;52:321-327.
17. Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, random-
ized clinical study to evaluate the effect on cognitive function of topira-
mate compared with valproate as add-on therapy to carbamazepine in
patients with partial-onset seizures. Epilepsia 2000;41:1167-1178.
18. Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analy-
sis of randomized controlled trials in adults. Epilepsia 2000;41
(Suppl.1):66-71.
19. Crawford P. An audit of topiramate use in a general neurology clinic.
Seiz Eur J Epilep 1998;7:207-211.
20. Khan A, Faught E, Gillian F, Kuzniecky R. Acute psychotic symptoms
induced by topiramate. Seizure 1999;84:235-237.
21. Abou-Khalil B, Fakhoury T. Neuropsychiatric profile of high-dose
topiramate. Epilepsia 1997;38(Suppl 8):207.
22. Khan A, Faught E, Kuzniecky R, Gilliam F, Laich E. Acute psychotic
symptoms induced by topiramate. Epilepsia 1997;38(Suppl 8):97.
23. Trimble MR, Rusch N, Betts T, Crawford PM. Psychiatric symptoms
after therapy with new antiepileptic drugs: psychopathological and
seizure related variables. Seizure 2000;9:249-254.
24. Bialer M. Comparative pharmacokinetics of the newer antiepileptic
drugs. Clin Pharmacokinet 1993;24:441-452.
25. Sadzot B. Pharma clinics. Medication of the month: topiramate
(topamax). Rev Med Liege 2000;55:114-116.
26. Herranz JL. Current data on topiramate. Rev Neurol 2000;30 (Suppl.1):
32-36.
27. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug
interactions with carbamazepine: an update. Clin Pharmacokinet 1996;
31:198-214.
28. Bourgeois BF. Drug interaction profile of topiramate. Epilepsia
1996;37(Suppl 2):14-17.
29. Bazire S. Psychotropic Drug Directory 2000. The professionals’ pocket
handbook and aide memoire. London: Quay Books Division 2000;257-
275.
30. World Health Organization. The ICD-10 classification of mental and
behavioural disorders: clinical descriptions and diagnostic guidelines.
Geneva: WHO, 1992.
